LOGIN  |  REGISTER
Chimerix

embecta to Participate in Investor Events

May 27, 2025 | Last Trade: US$10.73 0.13 1.23

PARSIPPANY, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor events:

2025 Goldman Sachs Tenth Annual Leveraged Finance and Credit Conference

  • Management will host one-on-one investor meetings on Thursday, May 29, 2025, at Waldorf Astoria Monarch Beach Resort & Club, Dana Point, CA.

2025 Jefferies Global Healthcare Conference

  • Management will host a fireside session on Thursday, June 5, 2025, at 4:55 p.m. EDT, at the Marriott Marquis, New York City.

2025 Goldman Sachs 46th Annual Global Healthcare Conference

  • Management will host a fireside session on Tuesday, June 10, 2025, at 1:20 p.m. EDT, at the Loews Miami Beach Hotel, Miami, FL.

2025 Truist Securities MedTech Conference

  • Management will host one-on-one investor meetings on Tuesday, June 17, 2025, at the InterContinental, Boston, MA.

About embecta 

embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, and Instagram.

Contacts:

Media
Christian Glazar
Sr. Director, Corporate Communications
908-821-6922
Contact Media Relations
Investors
Pravesh Khandelwal
VP, Head of Investor Relations
551-264-6547
Contact IR

Chimerix

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page